Mirabegron is a modern therapeutic agent belonging to the class of beta-3 adrenergic agonists, primarily indicated for the management of overactive bladder and neurogenic detrusor overactivity. Overactive bladder is a condition characterized by frequent urination, sudden and urgent need to urinate, and episodes of incontinence, which can significantly affect daily life and confidence. By acting on the bladder’s smooth muscle, mirabegron relaxes the detrusor muscle during the storage phase, thereby increasing bladder capacity and reducing involuntary contractions. This mechanism allows patients to hold urine for longer periods, decreasing urgency and frequency. In children with neurogenic detrusor overactivity, often linked to neurological conditions such as spinal cord injury or multiple sclerosis, mirabegron helps improve bladder function and reduces the risk of complications associated with poor bladder control. The medication is also used in combination with other agents like solifenacin when single therapy does not provide sufficient relief. Importantly, mirabegron does not cure these conditions but provides long-term management, enabling patients to regain control over bladder habits and improve their quality of life. With consistent use under medical supervision, mirabegron plays a vital role in restoring confidence, independence, and comfort for individuals struggling with bladder dysfunction.